Tongji Hospital
CompanyChinaFounded 1900
Tongji Hospital develops one asset, in phase 1 (Sanggua tablets in impaired glucose tolerance). Mostly supplement acting on Insulin/IGF-1 signalling and lipid and ceramide metabolism; based in China, founded in 1900.
- 1
- Asset
- Furthest
- Phase 1
- 29
- Trials
- 0
- Signals
Pipeline
1TCM herbal formula that lowers blood glucose and improves lipid profiles
Phase 1, Supplement, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, impaired glucose tolerance, type 2 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials50
- Integrity notices10
- Similar companies6
Papers
BASIC AND CLINICAL ASPECTS OF VASCULAR AGING
GSA 2024 abstract, 1 Jan 2025
Updated 12 Oct 2026 · 52 sources